Your shopping cart is currently empty

AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $59 | In Stock | In Stock | |
| 5 mg | $165 | In Stock | In Stock | |
| 10 mg | $243 | In Stock | In Stock | |
| 25 mg | $397 | In Stock | In Stock | |
| 50 mg | $597 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $195 | In Stock | In Stock |
| Description | AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies. |
| Targets&IC50 | CDK9:4 nM (IC50) |
| In vitro | Short-term administration of AZD4573 induced a swift, dose- and time-dependent reduction in cellular pSer2-RNAPII levels, which in turn activated caspase 3, leading to apoptosis across a wide spectrum of hematological cancer cell lines. Notably, caspase activation exhibited an EC50 of 13.7 nM in the acute myeloid leukemia model MV4-11. |
| In vivo | AZD4573 demonstrates a short half-life (<1 hour) in multiple species (dog, rat, monkey) and possesses good solubility for intravenous administration. |
| Molecular Weight | 429.94 |
| Formula | C22H28ClN5O2 |
| Cas No. | 2057509-72-3 |
| Smiles | CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1 |
| Relative Density. | 1.39 g/cm3 (Predicted) |
| Storage | store at low temperature,keep away from direct sunlight | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 118.75 mg/mL (276.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.